Scroll To Top




Sangamo BioSciences has launched a Phase I clinical trial of experimental medication SB-728-T, which aims to suppress HIV by modifying a portion of human DNA to prevent immune system cells from creating CCR5 surface receptors. The company believes a one-time exposure to the medication would create a permanent population of CD4 cells naturally resistant to HIV. --------------------- HIVers who experience treatment failure on an Aptivus-based regimen will still likely benefit later from a Prezista-based regimen, according to a study in the Journal of Acquired Immune Deficiency Syndromes. More than half of HIVers who began Prezista after a failed Aptivus regimen showed improvements in viral suppression. --------------------- A once-daily regimen of Viramune, Viread, and Epivir is associated with early virologic failure, researchers warn in the Journal of Antimicrobial Chemotherapy. More than 22% of HIVers in a study who were taking the combination experienced early nonresponse. --------------------- An ongoing Phase III clinical trial of integrase inhibitor Isentress has shown the medication is as effective in reducing viral levels in treatment-naive HIVers as the nonnucleoside analog Sustiva. Isentress is currently approved for only treatment-experienced patients. --------------------- A meta-analysis of 11 previous clinical trials published in the journal Clinical Infectious Diseases has proved what HIV caregivers had believed: HIVers adhere better to once-daily antiretroviral regimens than those taken more frequently. --------------------- Early studies of experimental anti-HIV drugs GS-9350, developed by Gilead Sciences, and SPI-452, developed by Sequoia Pharmaceuticals, have shown that the compounds may eventually rival protease inhibitor Norvir as drug-boosting agents in antiretroviral cocktails; both have chemical mechanisms similar to Norvir. --------------------- Osteoporosis medication zoledronate is effective in improving bone loss in HIV-positive adults, a study in the journal AIDS has shown. HIVers taking zoledronate for 12 months posted significant improvements in bone density, particularly in the hips. --------------------- British researchers report a case study of a 45-year-old HIV-positive man who suppressed HIV viral levels through use of only the anti-hepatitis B medication Tyzeka. The scientists believe the hepatitis treatment has anti-HIV activity and are planning additional studies of the drug. --------------------- A Phase II/IIb human clinical trial of the experimental HIV microbicide PRO2000 has shown that the gel was at least 30% effective in preventing HIV transmission from men to women during sex. --------------------- A human trial of the experimental nonnuke gel UC781, under development as a vaginal microbicide, has shown the gel is also safe and well-tolerated for use as a rectal HIV preventive product, according to University of California, Los Angeles, researchers. --------------------- Researchers at Oregon Health and Science University are developing an experimental preventive HIV vaccine to prime effector memory T cells to recognize and attack the virus when it first penetrates the body's mucosal tissues. Animal tests have shown the technique protected two thirds of vaccinated subjects.

Out Subscription Lil Nas XAdvocateChannel promotion

From our Sponsors

Most Popular

Fifth Person Cured of HIV

Latest Stories